Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Epidemiologic Notes and Reports Group A Beta-Hemolytic Streptococcal Bacteremia -- Colorado, 1989

From January through August 1989, group A beta-hemolytic Streptococcus (GABHS) was isolated from blood cultures obtained from 19 patients who had been admitted to a hospital in metropolitan Denver, Colorado. In comparison, this organism was cultured from blood from eight patients in 1988 and three in 1987 at this hospital (Figure 1). The Colorado Department of Health was notified of this increase, and in August, the department reviewed these patients' medical charts to describe GABHS bacteremia cases and to determine whether they represented community-acquired disease, nosocomial acquisition, or laboratory artifact.

Patients ranged in age from 3 weeks to 96 years (median: 67 years); 12 were male. All but one were residents of Colorado when hospitalized; 16 patients lived in the Denver metropolitan area. Twelve patients were admitted from private residences and four from nursing homes; three were transferred from acute- or extended-care facilities.

For 13 patients, a blood specimen was obtained within 6 hours of arrival at the hospital; 12 patients had presenting manifestations consistent with bacteremia or sepsis (primarily fever, chills, rigors, and a focus of infection). In only three patients was bacteremia first documented greater than 48 hours after hospitalization.

Seven patients had no identified source of bacteremia; four had a possible cutaneous source of infection (cellulitis, impetigo, open sores, or an abscess); seven had pneumonia, and one had both cutaneous and respiratory infections. Two of the seven without identified sources of infection developed GABHS bacteremia following major trauma in motor vehicle crashes. A third patient developed GABHS bacteremia following elective laser hemorrhoidectomy. Two patients developed acute respiratory distress syndrome; two developed acute renal failure; and nine (47%) died after developing GABHS bacteremia.

Eight group A Streptococcus blood culture isolates from this hospital were sent to CDC for typing. Three were M-type 1, T-type 1; three were M-type 3, T-type 3/13; and two were not typable.

Retrospective surveys of this and 17 other metropolitan Denver hospital microbiology laboratories identified 73 cases of GABHS bacteremia between January and August--a rate of seven cases per 100,000 per year in the general population of the Denver metropolitan area.

Active surveillance for GABHS bacteremia was established in September 1989 in metropolitan Denver. Bacterial isolates are sent to CDC for analysis, and ongoing case investigation is examining potential explanations for the increasing incidence of group A streptococcal disease and possible risk factors, such as age, underlying illnesses, socioeconomic status, and race/ethnicity. Reported by: C Voeck, N Armstrong, F Trail, M Wheeler, M Roe, J Todd, MD, RE Hoffman, MD, State Epidemiologist, Colorado Dept of Health. Div of Field Svcs, Epidemiology Program Office; Respiratory Diseases Br, Div of Bacterial Diseases, Center for Infectious Diseases, CDC.

Editorial Note

Editorial Note: During the last half century, the incidence of severe infections with group A Streptococcus (including bacteremia, puerperal sepsis, and scarlet fever) and nonsuppurative sequelae (such as rheumatic fever) has decreased markedly in the United States. Potential explanations for this decline may relate to antibiotic therapy, improved living conditions, and decreased virulence of the infecting organism (1). Recently, however, group A streptococcal infections have re-emerged as a public health problem. In 1985 and 1986, clusters of patients with rheumatic fever were reported from several areas (2-6), and since 1987, a severe syndrome associated with group A streptococcal infection (streptococcal toxic-shock-like syndrome) has been recognized (7,8).

The findings in Denver are consistent with a trend toward increasing rates of GABHS bacteremia. While a direct comparison of the GABHS bacteremia incidence rate in Denver for 1989 and for previous years is not possible because of incomplete laboratory records, the 1989 rate is more than double the most recent population-based estimate of three cases per 100,000 persons per year from Charleston County, South Carolina (1985-1987) (CDC, unpublished data). In addition, during 1989, CDC received an increased number of reports of GABHS bacteremia from other areas in the United States and serotyped strains from several Scandinavian countries that have increased rates of GABHS bacteremia. These reports suggest widespread changes in the epidemiology of group A streptococcal disease.

The descriptive epidemiology of GABHS bacteremia in the Denver patients is similar to that in previous reports (9,10). Even though all age groups may be affected, disease occurs primarily in the elderly, including nursing home residents. Underlying medical conditions in affected persons may include chronic debilitating disease, immunosuppressive illness or medication, and intravenous-drug use. In addition, surgery, traumatic injury, or other disruption of the cutaneous barrier may predispose persons to invasive infection. Meningitis, endocarditis, osteomyelitis, septic arthritis, and genitourinary infections can occur in association with bacteremia. Despite appropriate therapy, illness can progress to shock, disseminated intravascular coagulation, and death; reported mortality rates range from 5% to 45% (9).

Streptococcal toxic-shock-like syndrome also has been reported recently from the Rocky Mountain area (7). This condition has been associated with pyrogenic exotoxin-producing group A streptococcal strains. Clinical features include fever, shock, localized erythema, renal failure, severe tissue injury (myositis and fasciitis), and adult respiratory distress syndrome; bacteremia may occur and illness is often fatal (7,8). The clinical manifestations in some of the Denver patients were compatible with this syndrome.

Factors contributing to the apparent recent increase in GABHS bacteremia are unclear. No single serotype, to suggest a common source, was found in the isolates from Denver. Serologic typing of group A streptococcal strains based on antigenic differences in the M-protein suggests that an increase in the proportion of virulent organisms may play a role. M-types 1 and 3, comprising 75% of the Denver isolates, may be more invasive and more likely to cause clusters of infection than most other streptococcal M-types (11). Analysis of serotyping data from isolates submitted to CDC since 1972 shows an increase in the proportion of these two M-types in the 1980s (11).

Efforts to prevent and control invasive group A streptococcal disease should be directed at surveillance to establish the incidence of this problem in different geographic areas; further epidemiologic studies of toxic-shock-like syndrome; and improved understanding of the roles of immune responses, exotoxin, and other virulence factors. Physicians should continue to diagnose and treat mild streptococcal infections to prevent their progression to severe invasive disease.

On July 14, 1989, CDC notified state and territorial health officials of a possible increase in severe group A streptococcal infections and requested that clusters of invasive group A streptococcal infection or illness in previously healthy persons be reported through state health departments to the Respiratory Diseases Branch, Division of Bacterial Diseases, Center for Infectious Diseases, CDC; telephone (404) 639-3021.

References

  1. Quinn RW. Epidemiology of group A streptococcal

infections--their changing frequency and severity. Yale J Biol Med 1982;55:265-70.

2. Veasy LG, Wiedmeier SE, Orsmond GS, et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med 1987;316:421-7.

3. Wald ER, Dashefsky B, Feidt C, Chiponis D, Byers C. Acute rheumatic fever in western Pennsylvania and the tristate area. Pediatrics 1987;80:371-4.

4. Hosier DM, Craenen JM, Teske DW, Wheller JJ. Resurgence of acute rheumatic fever. Am J Dis Child 1987;141:730-3.

5. CDC. Acute rheumatic fever among Army trainees--Fort Leonard Wood, Missouri, 1987-1988. MMWR 1988;37:519-22.

6. CDC. Acute rheumatic fever at a Navy training center--San Diego, California. MMWR 1988;37:101-4.

7. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989;321:1-8.

8. Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 1987;317:146-9.

9. Bibler MR, Rouan GW. Cryptogenic group A streptococcal bacteremia: experience at an urban general hospital and review of the literature. Rev Infect Dis 1986;8:941-51. 10. Duma RJ, Weinberg AN, Medrek TF, Kunz LJ. Streptococcal infections: a bacteriologic and clinical study of streptococcal bacteremia. Medicine 1969;48:87-127. 11. Schwartz B, Facklam RR, Elliott J, Bosley G, Franklin R, Pigott N. Trends in group A streptococcal types, 1972 to 1988: the increasing proportion of rheumatogenic and invasive strains (Abstract). Presented at the Lancefield Society Meeting, Houston, Texas, Sept. 22, 1989.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.


All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

 
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #